HK1205503A1 - Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system // - Google Patents
Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system //Info
- Publication number
- HK1205503A1 HK1205503A1 HK15106010.6A HK15106010A HK1205503A1 HK 1205503 A1 HK1205503 A1 HK 1205503A1 HK 15106010 A HK15106010 A HK 15106010A HK 1205503 A1 HK1205503 A1 HK 1205503A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- disorders
- preventing
- nervous system
- central nervous
- novel compounds
- Prior art date
Links
- 208000015439 Lysosomal storage disease Diseases 0.000 title 1
- 210000003169 central nervous system Anatomy 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000003412 degenerative effect Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
Classifications
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10B—ELECTRONIC MEMORY DEVICES
- H10B12/00—Dynamic random access memory [DRAM] devices
- H10B12/01—Manufacture or treatment
- H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
- H10B12/03—Making the capacitor or connections thereto
- H10B12/033—Making the capacitor or connections thereto the capacitor extending over the transistor
- H10B12/0335—Making a connection between the transistor and the capacitor, e.g. plug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
- H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
- H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
- H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic Table or AIIIBV compounds with or without impurities, e.g. doping materials
- H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
- H01L21/31—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to form insulating layers thereon, e.g. for masking or by using photolithographic techniques; After treatment of these layers; Selection of materials for these layers
- H01L21/3105—After-treatment
- H01L21/311—Etching the insulating layers by chemical or physical means
- H01L21/31105—Etching inorganic layers
- H01L21/31111—Etching inorganic layers by chemical means
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
- H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
- H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
- H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic Table or AIIIBV compounds with or without impurities, e.g. doping materials
- H01L21/30—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26
- H01L21/31—Treatment of semiconductor bodies using processes or apparatus not provided for in groups H01L21/20 - H01L21/26 to form insulating layers thereon, e.g. for masking or by using photolithographic techniques; After treatment of these layers; Selection of materials for these layers
- H01L21/3205—Deposition of non-insulating-, e.g. conductive- or resistive-, layers on insulating layers; After-treatment of these layers
- H01L21/321—After treatment
- H01L21/3213—Physical or chemical etching of the layers, e.g. to produce a patterned layer from a pre-deposited extensive layer
- H01L21/32139—Physical or chemical etching of the layers, e.g. to produce a patterned layer from a pre-deposited extensive layer using masks
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L28/00—Passive two-terminal components without a potential-jump or surface barrier for integrated circuits; Details thereof; Multistep manufacturing processes therefor
- H01L28/40—Capacitors
- H01L28/60—Electrodes
- H01L28/82—Electrodes with an enlarged surface, e.g. formed by texturisation
- H01L28/90—Electrodes with an enlarged surface, e.g. formed by texturisation having vertical extensions
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10B—ELECTRONIC MEMORY DEVICES
- H10B12/00—Dynamic random access memory [DRAM] devices
- H10B12/01—Manufacture or treatment
- H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
- H10B12/03—Making the capacitor or connections thereto
- H10B12/033—Making the capacitor or connections thereto the capacitor extending over the transistor
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10B—ELECTRONIC MEMORY DEVICES
- H10B12/00—Dynamic random access memory [DRAM] devices
- H10B12/01—Manufacture or treatment
- H10B12/02—Manufacture or treatment for one transistor one-capacitor [1T-1C] memory cells
- H10B12/05—Making the transistor
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10B—ELECTRONIC MEMORY DEVICES
- H10B12/00—Dynamic random access memory [DRAM] devices
- H10B12/01—Manufacture or treatment
- H10B12/09—Manufacture or treatment with simultaneous manufacture of the peripheral circuit region and memory cells
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10B—ELECTRONIC MEMORY DEVICES
- H10B12/00—Dynamic random access memory [DRAM] devices
- H10B12/30—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells
- H10B12/31—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells having a storage electrode stacked over the transistor
- H10B12/315—DRAM devices comprising one-transistor - one-capacitor [1T-1C] memory cells having a storage electrode stacked over the transistor with the capacitor higher than a bit line
Landscapes
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Power Engineering (AREA)
- Organic Chemistry (AREA)
- Manufacturing & Machinery (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Computer Hardware Design (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261616159P | 2012-03-27 | 2012-03-27 | |
PCT/US2013/029612 WO2013148103A1 (fr) | 2012-03-27 | 2013-03-07 | Nouveaux composés pour la prévention et/ou le traitement des troubles de stockage des lysosomes et/ou des troubles dégénératifs du système nerveux central |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1205503A1 true HK1205503A1 (en) | 2015-12-18 |
Family
ID=47902369
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15106010.6A HK1205503A1 (en) | 2012-03-27 | 2015-06-24 | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system // |
Country Status (9)
Country | Link |
---|---|
US (3) | US9464050B2 (fr) |
EP (1) | EP2831043B1 (fr) |
AU (1) | AU2013240486B2 (fr) |
CA (1) | CA2868459A1 (fr) |
ES (1) | ES2924829T3 (fr) |
HK (1) | HK1205503A1 (fr) |
MX (1) | MX354127B (fr) |
NZ (1) | NZ630612A (fr) |
WO (1) | WO2013148103A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE028129T2 (en) * | 2009-10-19 | 2016-11-28 | Amicus Therapeutics Inc | New preparations for the prevention and / or treatment of lysosomal storage disorders |
US9796680B2 (en) | 2013-12-23 | 2017-10-24 | Alectos Therapeutics Inc. | Glucocerebrosidase modulators and uses thereof |
ES2771849T3 (es) * | 2014-02-12 | 2020-07-07 | Amicus Therapeutics Inc | Derivados de azúcares que comprenden restos que contienen azufre, métodos para prepararlos y métodos para emplearlos en el tratamiento de MPS IIIC |
US10179128B2 (en) | 2015-08-31 | 2019-01-15 | Amicus Therapeutics, Inc. | Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system |
WO2018122775A1 (fr) | 2016-12-29 | 2018-07-05 | Minoryx Therapeutics S.L. | Composés hétéroaryle et leur utilisation |
US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
DE69221484T2 (de) | 1991-04-25 | 1998-02-19 | Univ Brown Res Found | Implantierbare, biokompatible immunisolator-trägersubstanz zum abgeben ausgesuchter, therapeutischer produkte |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
CZ286632B6 (cs) | 1992-09-29 | 2000-05-17 | Inhale Therapeutic Systems | Farmaceutický prostředek |
FR2718357B1 (fr) | 1994-04-06 | 1997-10-03 | Defarges Alain Moreau | Perfectionnements apportés à un dispositif d'injection par jet sans aiguille. |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5780014A (en) | 1995-04-14 | 1998-07-14 | Inhale Therapeutic Systems | Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin |
US5654007A (en) | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
US6794694B2 (en) | 2000-12-21 | 2004-09-21 | Agere Systems Inc. | Inter-wiring-layer capacitors |
JP4060572B2 (ja) | 2001-11-06 | 2008-03-12 | 株式会社東芝 | 半導体記憶装置及びその製造方法 |
KR100446293B1 (ko) | 2002-01-07 | 2004-09-01 | 삼성전자주식회사 | 저항체를 포함하는 반도체 소자 제조 방법 |
JP2003273230A (ja) | 2002-03-19 | 2003-09-26 | Nec Electronics Corp | 半導体装置及びその製造方法 |
US6720232B1 (en) | 2003-04-10 | 2004-04-13 | Taiwan Semiconductor Manufacturing Company | Method of fabricating an embedded DRAM for metal-insulator-metal (MIM) capacitor structure |
EP1682134A4 (fr) * | 2003-11-12 | 2008-10-15 | Amicus Therapeutics Inc | Derives de gluco-imidazole et de polyhydroxycyclohexenyl-amine pour traiter la maladie de gaucher |
US7425740B2 (en) | 2005-10-07 | 2008-09-16 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method and structure for a 1T-RAM bit cell and macro |
JP2007201101A (ja) | 2006-01-25 | 2007-08-09 | Nec Electronics Corp | 集積回路装置および回路製造方法 |
WO2007140212A2 (fr) | 2006-05-24 | 2007-12-06 | Amicus Therapeutics, Inc. | Sel de tartrate d'isofagomine et ses méthodes d'utilisation |
MX2009011473A (es) | 2007-04-26 | 2010-01-18 | Amicus Therapeutics Inc | Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas. |
US8321148B2 (en) | 2008-10-24 | 2012-11-27 | Amicus Therapeutics, Inc. | Multiple compartment dosing model |
HUE028129T2 (en) * | 2009-10-19 | 2016-11-28 | Amicus Therapeutics Inc | New preparations for the prevention and / or treatment of lysosomal storage disorders |
DK2490712T3 (en) * | 2009-10-19 | 2015-10-05 | Amicus Therapeutics Inc | PROCESS FOR THE TREATMENT OF ALZHEIMER'S DISEASE BY USING Pharmacological chaperones TO INCREASE ACTIVITY OF GANGLIOSIDASER |
WO2011049736A1 (fr) | 2009-10-19 | 2011-04-28 | Amicus Therapeutics, Inc. | Nouvelles compositions pour prévenir et/ou traiter des troubles dégénératifs du système nerveux central |
JP2012064627A (ja) | 2010-09-14 | 2012-03-29 | Elpida Memory Inc | 半導体装置の製造方法 |
JP5689392B2 (ja) | 2011-09-02 | 2015-03-25 | ルネサスエレクトロニクス株式会社 | 半導体装置及び半導体装置の製造方法 |
KR102023720B1 (ko) | 2012-09-03 | 2019-09-20 | 엘지이노텍 주식회사 | 보이스 코일 모터 |
-
2013
- 2013-03-07 NZ NZ630612A patent/NZ630612A/en not_active IP Right Cessation
- 2013-03-07 EP EP13710951.8A patent/EP2831043B1/fr active Active
- 2013-03-07 MX MX2014011612A patent/MX354127B/es active IP Right Grant
- 2013-03-07 CA CA2868459A patent/CA2868459A1/fr not_active Abandoned
- 2013-03-07 US US14/387,646 patent/US9464050B2/en active Active
- 2013-03-07 ES ES13710951T patent/ES2924829T3/es active Active
- 2013-03-07 WO PCT/US2013/029612 patent/WO2013148103A1/fr active Application Filing
- 2013-03-07 AU AU2013240486A patent/AU2013240486B2/en not_active Ceased
-
2015
- 2015-06-24 HK HK15106010.6A patent/HK1205503A1/xx unknown
-
2016
- 2016-10-10 US US15/289,283 patent/US9750733B2/en active Active
-
2017
- 2017-08-31 US US15/692,765 patent/US10224333B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20150050263A1 (en) | 2015-02-19 |
US20170365609A1 (en) | 2017-12-21 |
CA2868459A1 (fr) | 2013-10-03 |
US10224333B2 (en) | 2019-03-05 |
MX354127B (es) | 2018-02-14 |
AU2013240486A1 (en) | 2014-09-25 |
US9464050B2 (en) | 2016-10-11 |
WO2013148103A1 (fr) | 2013-10-03 |
EP2831043A1 (fr) | 2015-02-04 |
AU2013240486B2 (en) | 2017-10-26 |
EP2831043B1 (fr) | 2022-07-27 |
US9750733B2 (en) | 2017-09-05 |
NZ630612A (en) | 2016-11-25 |
MX2014011612A (es) | 2014-10-17 |
ES2924829T3 (es) | 2022-10-11 |
US20170020853A1 (en) | 2017-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267066B (en) | Activin-actrii antagonists and their use for the treatment of bone and other disorders | |
HK1214553A1 (zh) | 用於治療神經退行性疾病的拉喹莫德和普利多匹定 | |
HK1199814A1 (en) | Inhibition of adaptor associated kinase for the treatment of pain | |
IL225239A0 (en) | Compounds for the treatment of acne and related diseases | |
EP2827856A4 (fr) | Composés et compositions pour le traitement d'affections musculaires | |
HK1204474A1 (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
HK1205503A1 (en) | Novel compounds for preventing and/or treating lysosomal storage disorders and/or degenerative disorders of the central nervous system // | |
HK1168005A1 (en) | Methods for preventing and or treating degenerative disorders of the central nervous system | |
HK1206721A1 (en) | 2-oxo-2,3-dihydro-indoles for the treatment of cns disorders cns 2--23-- | |
HK1199831A1 (en) | Composition for improving and or treating central nervous system degenerative disease | |
HK1219724A1 (zh) | 用於預防和/或治療中樞神經系統退行性失調的新穎組合物 | |
IL235127A (en) | Hpn-100 for use in the treatment of nitrogen-related diseases | |
EP2814474A4 (fr) | Procédés de traitement et de prévention de maladies et de troubles du système nerveux central | |
ZA201408060B (en) | Compositions and methods for the treatment of neurological disorders | |
ZA201408061B (en) | Compositions and methods for the treatment of neurological disorders | |
ZA201408058B (en) | Compositions and methods for the treatment of epilepsy | |
EP2902078A4 (fr) | Dispositif pour le traitement et les soins de la colonne vertébrale | |
EP2582832A4 (fr) | Méthodes et compositions pharmaceutiques pour traitement du système nerveux central animal pour troubles psychiatriques | |
EP2578206A4 (fr) | Composition pharmaceutique pour traiter les affections de la partie inférieure du système urogénital | |
KR101360143B9 (ko) | 몬소니아속 식물 추출물을 함유하는 치매 예방 또는 치료용 조성물 | |
GB201219696D0 (en) | Agents for the prevention and/or treatment of central nervous system damamge |